Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designed to exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, UK, focused on developing therapeutic drug discovery tools and platforms for pets. Founded in 2017, the company specializes in creating transgenic mouse platforms, such as Ky9 and Felyne, which produce therapeutic-quality antibody drugs specifically tailored for companion animals. Leveraging over thirty years of expertise in human drug development, PetMedix aims to generate a diverse repertoire of monoclonal antibodies that aligns with the immune systems of pets. This innovation enables veterinary professionals to provide effective and safe treatments, ultimately contributing to the health and well-being of animals.
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.
Riverlane is the most advanced quantum computing software developer
Founded in 2016 with a mission to empower people in business to make better decisions, Secondmind - The Decisions Company - is underpinned by years of award-winning, practical artificial intelligence (AI) and machine learning (ML) research, performed by a team of world-class researchers, data scientists and ML engineers. Secondmind closes the gap between people and AI, and supercharges decision-making with the Secondmind Decision Engine, an intuitive and insightful software platform that helps people in industries from supply chain to automotive predict, plan, influence outcomes, manage risk, and make complex decisions with ease and confidence. Secondmind is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.
Seldon Technologies Ltd. is a company based in Shoreditch, United Kingdom, that specializes in open-source machine learning deployment. Founded in 2014, Seldon offers a platform called Seldon Deploy, which facilitates the transition from research and development to production for machine learning engineering teams, achieving efficiency gains of up to 84%. The platform provides essential features such as audit trails, compliance approvals, and detailed model explanations. Seldon's open-source projects are recognized for their excellence in model serving, monitoring, and explanations, with over 2.5 million installations and 250,000 models deployed. The company serves a diverse clientele, including major enterprises in technology, pharmaceuticals, automotive, finance, and retail, and its solutions are integrated with leading machine learning platforms from companies like Google and Red Hat. Seldon has also garnered recognition as a "Cool Vendor" in AI Core technologies by Gartner in 2020.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
GeoSpock Limited is a spatial big data platform company based in Cambridge, United Kingdom, with additional offices in Tokyo and Singapore. Founded in 2013, it specializes in developing a data indexing platform that provides analytics, visualization, and insights across various scales of data. The company offers products such as GeoSpock DB Discovery and GeoSpock DB Enterprise, which are cloud-based services designed to manage and analyze location-tagged information. These tools facilitate dynamic data fusion and enable users to perform complex queries for performance analytics. GeoSpock's platform can be utilized in a range of applications, from real-time tracking of logistics fleets to optimizing operations in smart cities, helping to uncover hidden patterns and improve decision-making. By harnessing trillions of data points in seconds, GeoSpock aims to transform business operations and contribute to sustainability efforts, such as reducing traffic congestion.
AudioTelligence Ltd is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in real-time audio processing technology aimed at improving automatic speech recognition (ASR) systems. The company utilizes an innovative approach known as blind audio signal separation, which allows it to effectively distinguish target voices from background noise without relying on high-quality microphones. This technology enhances the clarity and intelligibility of audio, making it easier for humans and voice-activated devices to engage in conversations despite challenging acoustic environments. AudioTelligence's solutions outperform traditional methods such as beamforming and spectral masking, positioning the company as a leader in the field of audio enhancement.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.
PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.
Riverlane is the most advanced quantum computing software developer
Audio Analytic Ltd. specializes in sound recognition software aimed at enhancing the contextual awareness of consumer technology. The company offers a range of products, including its ai3TM analytics software, which classifies and recognizes various sounds, and AuditoryNET, which utilizes a dedicated machine learning pipeline for optimized sound recognition. Their offerings enable devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to detect and interpret sounds beyond speech and music, contributing to applications in safety, security, wellbeing, health, entertainment, and communication. Established in 2008 and based in Cambridge, UK, with an additional office in San Francisco, Audio Analytic serves original equipment manufacturers and chip providers across multiple industries, including consumer electronics and acoustics.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Founded in 2016 with a mission to empower people in business to make better decisions, Secondmind - The Decisions Company - is underpinned by years of award-winning, practical artificial intelligence (AI) and machine learning (ML) research, performed by a team of world-class researchers, data scientists and ML engineers. Secondmind closes the gap between people and AI, and supercharges decision-making with the Secondmind Decision Engine, an intuitive and insightful software platform that helps people in industries from supply chain to automotive predict, plan, influence outcomes, manage risk, and make complex decisions with ease and confidence. Secondmind is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.
Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to help organizations manage and distribute their media libraries. The company offers Imagen2, a media asset management and publishing system, ImagenCloud, a cloud-based platform for managing and publishing videos and images, and Orbital, a compliance recording system. Founded in 1991 and based in Willingham, United Kingdom, Imagen serves a diverse clientele that includes the Ministry of Defence, The Police, the BBC, and British Telecom. The company’s modular enterprise video platform enables clients to securely manage, search, and monetize both current and archived media content, facilitating efficient storage and distribution through a user-friendly web interface.
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
CEDAR Audio is a specialized company focused exclusively on audio restoration and speech enhancement across various industries, including film, television, radio broadcast, and audio forensic investigation. Founded in 1988 after extensive research supported by the British Library National Sound Archive, the company is headquartered in Cambridge, UK, and maintains significant academic partnerships with Cambridge University, enhancing its expertise in digital signal processing. CEDAR Audio is recognized for its innovative hardware-based systems that effectively suppress noise in live environments, such as conferences, performances, and sporting events, allowing sound recordists to deliver clean audio without spectral artifacts. The company is dedicated to advancing audio restoration technology and offers a range of leading products while prioritizing exceptional customer support, earning numerous accolades in this area.
AudioTelligence Ltd is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in real-time audio processing technology aimed at improving automatic speech recognition (ASR) systems. The company utilizes an innovative approach known as blind audio signal separation, which allows it to effectively distinguish target voices from background noise without relying on high-quality microphones. This technology enhances the clarity and intelligibility of audio, making it easier for humans and voice-activated devices to engage in conversations despite challenging acoustic environments. AudioTelligence's solutions outperform traditional methods such as beamforming and spectral masking, positioning the company as a leader in the field of audio enhancement.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Nstream, formerly known as Swim.Ai, Inc., is a technology company that specializes in advanced analytics software for processing data at the edge of networks. Founded in 2015 and headquartered in San Jose, California, Nstream offers the SWIM EDX platform, which transforms streaming edge data into real-time insights and predictions, addressing the challenges associated with big data. The company serves a diverse clientele, including original equipment manufacturers, service providers, enterprises, cities, and Internet of Things (IoT) vendors. Nstream's solutions integrate edge computing, machine learning, and self-training digital twins within a mesh architecture. Additionally, its Swim Continuum platform enables organizations to build and manage continuous intelligence applications, providing operational decision support and situational awareness through real-time and contextual data analysis. With a focus on enhancing human decision-making, Nstream aims to deliver efficient performance and seamless interoperability with existing enterprise systems.
Undo Ltd. develops innovative debugging tools tailored for software developers, architects, product managers, and application engineers. The company offers a live recorder that captures and replays software execution, enabling users to identify programming errors and debug them effectively. Its flagship product, UndoDB, serves as an interactive reversible debugger specifically for C/C++ on Linux and Android platforms. Undo's technologies are utilized by major software companies across various industries, including data management, networking, electronic design automation, and finance, allowing developers to address complex challenges efficiently. By employing its unique record, rewind, and replay capabilities, Undo helps developers quickly diagnose and resolve issues in both production and testing environments, enhancing productivity and improving software quality. Founded in 2005, Undo is headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California.
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.
GeoSpock Limited is a spatial big data platform company based in Cambridge, United Kingdom, with additional offices in Tokyo and Singapore. Founded in 2013, it specializes in developing a data indexing platform that provides analytics, visualization, and insights across various scales of data. The company offers products such as GeoSpock DB Discovery and GeoSpock DB Enterprise, which are cloud-based services designed to manage and analyze location-tagged information. These tools facilitate dynamic data fusion and enable users to perform complex queries for performance analytics. GeoSpock's platform can be utilized in a range of applications, from real-time tracking of logistics fleets to optimizing operations in smart cities, helping to uncover hidden patterns and improve decision-making. By harnessing trillions of data points in seconds, GeoSpock aims to transform business operations and contribute to sustainability efforts, such as reducing traffic congestion.
Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.
Founded in 2016 with a mission to empower people in business to make better decisions, Secondmind - The Decisions Company - is underpinned by years of award-winning, practical artificial intelligence (AI) and machine learning (ML) research, performed by a team of world-class researchers, data scientists and ML engineers. Secondmind closes the gap between people and AI, and supercharges decision-making with the Secondmind Decision Engine, an intuitive and insightful software platform that helps people in industries from supply chain to automotive predict, plan, influence outcomes, manage risk, and make complex decisions with ease and confidence. Secondmind is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.
Z Factor Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company focuses on identifying and developing therapeutic agents to address alpha-1-antitrypsin deficiency, a genetic disorder that leads to significant health complications. Z Factor's research aims to design novel therapeutic solutions that correct the misfolding of the Z variant of alpha-1-antitrypsin, addressing a critical medical need. Current treatment options are limited, primarily relying on lung or liver transplantation and augmentation therapy. Through its innovative approach, Z Factor seeks to create effective therapies that could improve the quality of life for those affected by this condition.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
Audio Analytic Ltd. specializes in sound recognition software aimed at enhancing the contextual awareness of consumer technology. The company offers a range of products, including its ai3TM analytics software, which classifies and recognizes various sounds, and AuditoryNET, which utilizes a dedicated machine learning pipeline for optimized sound recognition. Their offerings enable devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to detect and interpret sounds beyond speech and music, contributing to applications in safety, security, wellbeing, health, entertainment, and communication. Established in 2008 and based in Cambridge, UK, with an additional office in San Francisco, Audio Analytic serves original equipment manufacturers and chip providers across multiple industries, including consumer electronics and acoustics.
Exvastat is a preclinical-stage pharmaceutical company established in 2016, focused on developing a treatment for acute respiratory distress syndrome (ARDS) using a repurposed drug already available for other medical indications. The company aims to address the significant mortality and debilitating complications associated with ARDS by inhibiting vascular leaks that contribute to pulmonary edema. By improving patient outcomes, Exvastat also seeks to lower the financial burden on healthcare providers caring for critically ill patients.
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to help organizations manage and distribute their media libraries. The company offers Imagen2, a media asset management and publishing system, ImagenCloud, a cloud-based platform for managing and publishing videos and images, and Orbital, a compliance recording system. Founded in 1991 and based in Willingham, United Kingdom, Imagen serves a diverse clientele that includes the Ministry of Defence, The Police, the BBC, and British Telecom. The company’s modular enterprise video platform enables clients to securely manage, search, and monetize both current and archived media content, facilitating efficient storage and distribution through a user-friendly web interface.
Undo Ltd. develops innovative debugging tools tailored for software developers, architects, product managers, and application engineers. The company offers a live recorder that captures and replays software execution, enabling users to identify programming errors and debug them effectively. Its flagship product, UndoDB, serves as an interactive reversible debugger specifically for C/C++ on Linux and Android platforms. Undo's technologies are utilized by major software companies across various industries, including data management, networking, electronic design automation, and finance, allowing developers to address complex challenges efficiently. By employing its unique record, rewind, and replay capabilities, Undo helps developers quickly diagnose and resolve issues in both production and testing environments, enhancing productivity and improving software quality. Founded in 2005, Undo is headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California.
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.
Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.
PervasID Limited, founded in 2011 and based in Cambridge, United Kingdom, specializes in the development of wide area passive RFID systems. The company emerged from research conducted at the University of Cambridge and focuses on providing location capabilities based on the EPC Class1 Gen2 standard. PervasID's technology employs fixed ultra-high frequency RFID to accurately detect passive tags over long distances, facilitating enhanced visibility into goods, assets, and people. Its innovative systems are designed to serve various industries, including retail, healthcare, supply chain and logistics, and aviation. The technology has been successfully deployed in multiple field trials, demonstrating its reliability and effectiveness in streamlining processes across diverse markets.
Fluidic Analytics Limited designs, develops, and manufactures equipment for the characterization of proteins in laboratory, medical, and consumer applications. The company provides Fluidity One, a product that enables in-solution sizing and quantification of native protein. The company also offers Fluidity One-W, a product that enables high sensitivity in-solution analysis of protein size and protein interaction kinetics. Its products are used for applications, including protein quality, interactions, aggregation, and sizing. The company serves scientists, clinics, and healthcare providers. Fluidic Analytics Limited was founded in 2013 and is based in Cambridge, United Kingdom.
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.
Audio Analytic Ltd. specializes in sound recognition software aimed at enhancing the contextual awareness of consumer technology. The company offers a range of products, including its ai3TM analytics software, which classifies and recognizes various sounds, and AuditoryNET, which utilizes a dedicated machine learning pipeline for optimized sound recognition. Their offerings enable devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to detect and interpret sounds beyond speech and music, contributing to applications in safety, security, wellbeing, health, entertainment, and communication. Established in 2008 and based in Cambridge, UK, with an additional office in San Francisco, Audio Analytic serves original equipment manufacturers and chip providers across multiple industries, including consumer electronics and acoustics.
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.
Jukedeck Limited is a London-based company that specializes in creating soundtracks for videos through artificial intelligence. Established in 2012, the company has developed technology that composes and adapts personalized music for various contexts, allowing users to generate original music autonomously. Jukedeck also offers an API that grants access to a library of royalty-free music, enabling users to create, browse, and edit their own soundtracks. This innovative approach utilizes deep neural networks to understand and facilitate music composition, enhancing creative processes for users. As of July 2019, Jukedeck operates as a subsidiary of Bytedance UK Limited.
GeoSpock Limited is a spatial big data platform company based in Cambridge, United Kingdom, with additional offices in Tokyo and Singapore. Founded in 2013, it specializes in developing a data indexing platform that provides analytics, visualization, and insights across various scales of data. The company offers products such as GeoSpock DB Discovery and GeoSpock DB Enterprise, which are cloud-based services designed to manage and analyze location-tagged information. These tools facilitate dynamic data fusion and enable users to perform complex queries for performance analytics. GeoSpock's platform can be utilized in a range of applications, from real-time tracking of logistics fleets to optimizing operations in smart cities, helping to uncover hidden patterns and improve decision-making. By harnessing trillions of data points in seconds, GeoSpock aims to transform business operations and contribute to sustainability efforts, such as reducing traffic congestion.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to help organizations manage and distribute their media libraries. The company offers Imagen2, a media asset management and publishing system, ImagenCloud, a cloud-based platform for managing and publishing videos and images, and Orbital, a compliance recording system. Founded in 1991 and based in Willingham, United Kingdom, Imagen serves a diverse clientele that includes the Ministry of Defence, The Police, the BBC, and British Telecom. The company’s modular enterprise video platform enables clients to securely manage, search, and monetize both current and archived media content, facilitating efficient storage and distribution through a user-friendly web interface.
Abcodia Ltd. is a company focused on the discovery and validation of molecular biomarkers for disease diagnosis and screening. Established in 2010 and based in London, it offers the Roca Test, a solution for the early detection of ovarian cancer, available to customers across various states in the United States as well as in the United Kingdom. Abcodia utilizes a unique longitudinal serum biobank and collaborates with prominent institutions and diagnostic companies to enhance the diagnostic development process. Through these efforts, the company aims to improve disease detection and contribute to better health outcomes.
Undo Ltd. develops innovative debugging tools tailored for software developers, architects, product managers, and application engineers. The company offers a live recorder that captures and replays software execution, enabling users to identify programming errors and debug them effectively. Its flagship product, UndoDB, serves as an interactive reversible debugger specifically for C/C++ on Linux and Android platforms. Undo's technologies are utilized by major software companies across various industries, including data management, networking, electronic design automation, and finance, allowing developers to address complex challenges efficiently. By employing its unique record, rewind, and replay capabilities, Undo helps developers quickly diagnose and resolve issues in both production and testing environments, enhancing productivity and improving software quality. Founded in 2005, Undo is headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.
Jukedeck Limited is a London-based company that specializes in creating soundtracks for videos through artificial intelligence. Established in 2012, the company has developed technology that composes and adapts personalized music for various contexts, allowing users to generate original music autonomously. Jukedeck also offers an API that grants access to a library of royalty-free music, enabling users to create, browse, and edit their own soundtracks. This innovative approach utilizes deep neural networks to understand and facilitate music composition, enhancing creative processes for users. As of July 2019, Jukedeck operates as a subsidiary of Bytedance UK Limited.
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to help organizations manage and distribute their media libraries. The company offers Imagen2, a media asset management and publishing system, ImagenCloud, a cloud-based platform for managing and publishing videos and images, and Orbital, a compliance recording system. Founded in 1991 and based in Willingham, United Kingdom, Imagen serves a diverse clientele that includes the Ministry of Defence, The Police, the BBC, and British Telecom. The company’s modular enterprise video platform enables clients to securely manage, search, and monetize both current and archived media content, facilitating efficient storage and distribution through a user-friendly web interface.